| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/01/2005 | EP1534390A2 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 06/01/2005 | EP1534368A1 Medicament dispenser |
| 06/01/2005 | EP1534367A1 Medicament dispenser |
| 06/01/2005 | EP1534338A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 06/01/2005 | EP1534314A1 A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction |
| 06/01/2005 | EP1534313A2 Ophthalmologic irrigation solutions and method |
| 06/01/2005 | EP1534306A2 Defensins: use as antiviral agents |
| 06/01/2005 | EP1534304A1 An analgesic agent for newborn or fetal subjects |
| 06/01/2005 | EP1534299A2 Methods for treating psychosis associated with interferon-alpha therapy |
| 06/01/2005 | EP1534298A2 Novel anticholesterol compositions and method for using same |
| 06/01/2005 | EP1534296A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 06/01/2005 | EP1534290A2 Novel inhibitors of kinases |
| 06/01/2005 | EP1534289A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders |
| 06/01/2005 | EP1534282A2 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| 06/01/2005 | EP1534278A2 Nitrosated proton pump inhibitors, compositions and methods of use |
| 06/01/2005 | EP1534276A2 Non-nucleoside reverse transcriptase inhibitors |
| 06/01/2005 | EP1534273A2 Modulators of the glucocorticoid receptor and method |
| 06/01/2005 | EP1534265A1 Combination of an aromatase inhibitor with a bisphosphonate |
| 06/01/2005 | EP1534264A2 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 06/01/2005 | EP1534259A2 Sulfonamides as potassium channel blockers |
| 06/01/2005 | EP1534258A2 AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION |
| 06/01/2005 | EP1534256A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/01/2005 | EP1534254A2 Method of promoting smoking cessation |
| 06/01/2005 | EP1534250A2 Electrospun amorphous pharmaceutical compositions |
| 06/01/2005 | EP1534243A1 Treating alzheimers using delipidated protein particles |
| 06/01/2005 | EP1534241A1 Transdermal aerosol compositions |
| 06/01/2005 | EP1534213A2 Water-based delivery systems |
| 06/01/2005 | EP1534191A2 Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
| 06/01/2005 | EP1534074A2 Combination therapy for the treatment of obesity |
| 06/01/2005 | EP1448794A4 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis |
| 06/01/2005 | EP1411926B1 Integrin inhibitors for the treatment of eye diseases |
| 06/01/2005 | EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors |
| 06/01/2005 | EP1383539A4 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 06/01/2005 | EP1335730B1 Use of pde5 inhibitors for the treatment of premature ejaculation |
| 06/01/2005 | EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 06/01/2005 | EP1218064B1 COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASEs CONTAINING A COMPOUND WHICH INHIBITS ICAM-LFA-1 INTERACTION AND A COMPOUND WHICH INHIBITS CD40-CD40 LIGAND INTERACTION |
| 06/01/2005 | EP1178977B1 Ion channel modulating agents |
| 06/01/2005 | EP1173205B1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| 06/01/2005 | EP1171160B1 Method and means for treating post-polio syndrome |
| 06/01/2005 | EP1143927B1 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 06/01/2005 | EP1042460B1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof |
| 06/01/2005 | EP0906433B1 Protein tyrosine phosphatases of hematopoietic cells |
| 06/01/2005 | CN1622957A IFNAR2 mutants, their production and use |
| 06/01/2005 | CN1622942A HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 06/01/2005 | CN1622816A Composition and method for augmenting kidney function |
| 06/01/2005 | CN1622814A Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 06/01/2005 | CN1622811A Use of alkylphosphocholines for the preventative treatment of protozoan diseases |
| 06/01/2005 | CN1622806A Method for the treatment of overactive bladder |
| 06/01/2005 | CN1622805A Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 06/01/2005 | CN1621092A Folic acid receptor targeted liposome medicine carrier, its preparation and application |
| 06/01/2005 | CN1621041A Pharmaceutical composition with pain easing function |
| 06/01/2005 | CN1621037A Application of Schisandrin-B in preparing medicine for treating tumor |
| 06/01/2005 | CN1621032A Application of microcapsule composition infusing to abdomen cavity for preventing carcinomatosis |
| 06/01/2005 | CN1203894C Anti-cancer medicine composition |
| 06/01/2005 | CN1203893C Anti-cancer medicine composition |
| 06/01/2005 | CN1203860C Application of Na-ion channel blocker and aspirin in preparing antalgic medicine for mammal |
| 06/01/2005 | CN1203852C Valdecoxib compositions |
| 06/01/2005 | CN1203851C Use of inhibitor produced or released by reactive oxygen metablite in producing pharmaceutical |
| 05/31/2005 | US6900367 Transgenic Drosophila melanogaster expressing a β42 in the eye |
| 05/31/2005 | US6900344 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 05/31/2005 | US6900329 MCH antagonists and their use in the treatment of obesity |
| 05/31/2005 | US6900323 The present invention is directed to a series of chemical entitites that express HIV-1 inhibitory activities. |
| 05/31/2005 | US6900241 Compositions for, and methods of, treating atherosclerosis |
| 05/31/2005 | US6900238 HIV protease inhibitors |
| 05/31/2005 | US6900234 Hypotensive agents; congestive heart failure; using mixture of enzyme inhibitors of renin, angiotensin converting enzyme and angiotensin antagonist |
| 05/31/2005 | US6900231 Aminopyridyl-substituted phenyl acetamides as protease inhibitors |
| 05/31/2005 | US6900226 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/31/2005 | US6900221 Crystalline polymorph of erlotinib hydrochloride; synthesis; treating cancer |
| 05/31/2005 | US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 05/31/2005 | US6900208 Antiinflammatory agents; osteoporosis; anticancer agents |
| 05/31/2005 | US6900205 Antidiabetic agents |
| 05/31/2005 | US6900187 TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| 05/31/2005 | US6900184 Synergistic mixture of piperacillin and tazobactam; controlling bacteria infections |
| 05/31/2005 | US6900055 Oxygen permeable biocompatible elastomer for propagating viable tissue; tissue engineering |
| 05/31/2005 | US6900027 Preparing biopsy of tumorous tissue and monitoring chemosensitivity to anticarcinogenic agents; antitumor agents |
| 05/31/2005 | US6900008 Methods and formulations for minimizing spasticity in blood vessel grafts |
| 05/31/2005 | US6899890 Bioadhesive drug delivery system |
| 05/31/2005 | US6899888 Suppressing bone disordes such as decalcification or fractures in humans having prostate gland cancers by administering antiestrogen selected from triphenylethylene or toremifene; hormone inhibitors |
| 05/31/2005 | US6899879 Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies |
| 05/31/2005 | US6899864 Kit and method for targeting of a diagnostic or therapeutic agent to target site in mammal having a pathological condition |
| 05/31/2005 | US6899700 Therapeutic agent delivery tampon |
| 05/26/2005 | WO2005047548A1 Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
| 05/26/2005 | WO2005047248A1 4-biarylyl-1-phenylazetidin-2-ones |
| 05/26/2005 | WO2005046797A2 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| 05/26/2005 | WO2005046796A2 Combinations of a cholesterol biosynthesis inhibitor and a soluble fiber for the treatment of conditions associated with elevated cholesterol levels |
| 05/26/2005 | WO2005046738A2 Virucidal activities of cetylpyridinium chloride |
| 05/26/2005 | WO2005046726A2 Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist |
| 05/26/2005 | WO2005046725A1 Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance |
| 05/26/2005 | WO2005046694A1 Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance |
| 05/26/2005 | WO2005046691A1 Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| 05/26/2005 | WO2005046689A2 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 05/26/2005 | WO2005046687A1 Use of selective opiate receptor modulators in the treatment of neuropathy |
| 05/26/2005 | WO2005046686A1 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
| 05/26/2005 | WO2005046678A1 Cancer treatment method |
| 05/26/2005 | WO2005046675A2 Methods for enhancing glutathione peroxidase activity |
| 05/26/2005 | WO2005046665A1 Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor |
| 05/26/2005 | WO2005046662A2 Hdl-boosting combination therapy complexes |
| 05/26/2005 | WO2005046660A1 MODULATING SUBSTANCES OF THE NITRIC OXID (NO) - CYCLIC GUANOSINE - 3’,5’- MONOPHOSPHATE (cGMP) SIGNALING PATHWAY FOR THE TREATMENT OF DENTAL DISORDERS |
| 05/26/2005 | WO2005046659A2 Migraine treatments including isovaleramide compounds and serotonin agonists |
| 05/26/2005 | WO2005046650A1 Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor |